Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.